This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.08% per year. These returns cover a period from January 1, 1988 through May 6, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
New Strong Sell Stocks for March 4th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today
New Strong Sell Stocks for February 27th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:
Colgate-Palmolive (CL) Up 7.6% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Colgate-Palmolive (CL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Procter & Gamble to Widen Naturals Line With This is L. Buyout
by Zacks Equity Research
Procter & Gamble (PG) is focusing on the fast-growing 'naturals' business line, with the acquisition of a natural ingredient-based women's products company, This is L.
Clorox (CLX) Earnings Surpass Estimates in Q2, Sales Miss
by Zacks Equity Research
Clorox (CLX) retains forecasts for fiscal 2019, which should benefit from ongoing cost-savings plans.
New Strong Sell Stocks for January 30th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today
Colgate (CL) Q4 Earnings Beat, Soft 2019 View Hurts Stock
by Zacks Equity Research
Colgate's (CL) fourth-quarter 2018 earnings and sales beat estimates on solid organic sales, and improved pricing. However, the company issues a soft earnings view for 2019.
Congressional Activities on Shutdown in Focus
by Zacks Equity Research
Congressional Activities on Shutdown in Focus
Asia, Congress Activity, Put Futures in the Green
by Mark Vickery
Market indexes are up in today's pre-market ??? the Dow in the green a healthy triple digits ??? despite a disappointing earnings call from Intel and comments from the Commerce Secretary yesterday.
Colgate-Palmolive (CL) Q4 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Colgate-Palmolive (CL) delivered earnings and revenue surprises of 1.37% and 0.97%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?
Should You Buy Colgate (CL) Ahead of Earnings?
by Zacks Equity Research
Colgate (CL) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
3 Soaps and Cleaning Materials Stocks Set to Beat Q4 Earnings
by Zacks Equity Research
The Soaps and Cleaning Materials industry remains lucrative, backed by product innovation, and cost-saving and restructuring efforts despite soft sales and margins woes.
Will Colgate (CL) Retain Earnings Trend in Q4 Despite Odds?
by Zacks Equity Research
Colgate (CL) witnesses soft top line and strained margins, owing to tough operating environment and higher costs. However, its beat or meet earnings trend is likely to continue in fourth-quarter 2018.
Colgate-Palmolive (CL) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Colgate-Palmolive (CL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will Procter & Gamble (PG) Retain Earnings Beat Trend in Q2?
by Zacks Equity Research
Procter & Gamble's (PG) strategic efforts such as product improvement and cost-saving plans are impressive. However, commodity cost inflation and adverse currency remain concerns.
5 Consumer Staples Stocks Set to Top Earnings Estimates in Q4
by Zacks Equity Research
There are various players in the consumer staples space that appear lucrative this earnings season, thanks to their efforts to counter the odds.
The Zacks Analyst Blog Highlights: Morgan Stanley, Intuitive Surgical, Colgate-Palmolive, Keurig Dr Pepper and Prudential Financial
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Morgan Stanley, Intuitive Surgical, Colgate-Palmolive, Keurig Dr Pepper and Prudential Financial
Top Research Reports for Morgan Stanley, Intuitive Surgical & Colgate-Palmolive
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, Morgan Stanley (MS), Intuitive Surgical, Inc. (ISRG) and Colgate-Palmolive Company (CL).
Colgate Stock Loses Ground: Can Strategies Aid a Turnaround?
by Zacks Equity Research
Colgate's (CL) grapples with soft sales and strained margins for quite a while now. Nevertheless, the company's cost-savings program appears promising.
Clorox's (CLX) 2020 Strategy on Track, Margin Woes Linger
by Zacks Equity Research
Clorox (CLX) benefits from 2020 strategy, expansion of e-commerce capabilities and brand management initiatives. However, dismal margins and soft fiscal earnings view are concerns.
Forget Colgate, Buy These 4 Consumer Stocks Instead for 2019
by Rajani Lohia
Colgate (CL) suffers due to higher raw material and freight costs as well as unfavorable currency rates. However, there are other stocks that are poised to benefit from favorable consumer trends.
Amedisys, Colgate-Palmolive, Deutsche, Societe General and Danske highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Amedisys, Colgate-Palmolive, Deutsche, Societe General and Danske highlighted as Zacks Bull and Bear of the Day
Colgate (CL) Stock Down 14.3% YTD: What You Should Know
by Zacks Equity Research
Colgate's (CL) dismal performance can be attributed to uncertain global markets. Also, a dismal sales trend is worrisome. However, the company's savings programs appear impressive.
Bear of the Day: Colgate-Palmolive (CL)
by Madeleine Johnson
Earnings estimated have fallen sharply for this consumer staples giant.
New Strong Sell Stocks for November 27th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today